Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graham J Mann

Showing results (91-100 of 183) with videos related to

Pageof 19
Sort By:
Pathology|March 30, 2016
Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision makingRicardo De Paoli-Iseppi, Peter A Johansson, Alexander M Menzies, et al.
Oncotarget|June 11, 2014
A highly recurrent RPS27 5'UTR mutation in melanomaKen Dutton-Regester, Jared J Gartner, Rafi Emmanuel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2006
Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancerMark Wong, Rosemary L Balleine, Elaine Y L Blair, et al.
Pathology|March 30, 2016
The molecular profile of metastatic melanoma in AustraliaMegan Lyle, Lauren E Haydu, Alexander M Menzies, et al.
Molecular Cancer Therapeutics|March 3, 2012
A high-throughput panel for identifying clinically relevant mutation profiles in melanomaKen Dutton-Regester, Darryl Irwin, Priscilla Hunt, et al.
The Australasian Journal of Dermatology|October 11, 2018
The steadily growing problem of lentigo maligna and lentigo maligna melanoma in Australia: Population-based data on diagnosis and managementPascale Guitera, Helena Collgros, Christine M Madronio, et al.
Mutation Research|August 29, 2009
Functional impairment of p16(INK4A) due to CDKN2A p.Gly23Asp missense mutationMaria Chiara Scaini, Elisabetta Rossi, Paula Lobao Antunes de Siqueira Torres, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 22, 2017
Neurotropic melanoma: an analysis of the clinicopathological features, management strategies and survival outcomes for 671 patients treated at a tertiary referral centerAlexander H R Varey, Chris Goumas, Angela M Hong, et al.
Oncotarget|August 26, 2015
Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genesJessamy C Tiffen, Dilini Gunatilake, Stuart J Gallagher, et al.
The British Journal of Dermatology|December 18, 2021
Independent evaluation of melanoma polygenic risk scores in UK and Australian prospective cohortsJulia Steinberg, Mark M Iles, Jin Yee Lee, et al.
Pageof 19

Showing results (91-100 of 183) with videos related to

Sort By:
Pageof 19
Pathology|March 30, 2016
Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision makingRicardo De Paoli-Iseppi, Peter A Johansson, Alexander M Menzies, et al.
Oncotarget|June 11, 2014
A highly recurrent RPS27 5'UTR mutation in melanomaKen Dutton-Regester, Jared J Gartner, Rafi Emmanuel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2006
Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancerMark Wong, Rosemary L Balleine, Elaine Y L Blair, et al.
Pathology|March 30, 2016
The molecular profile of metastatic melanoma in AustraliaMegan Lyle, Lauren E Haydu, Alexander M Menzies, et al.
Molecular Cancer Therapeutics|March 3, 2012
A high-throughput panel for identifying clinically relevant mutation profiles in melanomaKen Dutton-Regester, Darryl Irwin, Priscilla Hunt, et al.
The Australasian Journal of Dermatology|October 11, 2018
The steadily growing problem of lentigo maligna and lentigo maligna melanoma in Australia: Population-based data on diagnosis and managementPascale Guitera, Helena Collgros, Christine M Madronio, et al.
Mutation Research|August 29, 2009
Functional impairment of p16(INK4A) due to CDKN2A p.Gly23Asp missense mutationMaria Chiara Scaini, Elisabetta Rossi, Paula Lobao Antunes de Siqueira Torres, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 22, 2017
Neurotropic melanoma: an analysis of the clinicopathological features, management strategies and survival outcomes for 671 patients treated at a tertiary referral centerAlexander H R Varey, Chris Goumas, Angela M Hong, et al.
Oncotarget|August 26, 2015
Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genesJessamy C Tiffen, Dilini Gunatilake, Stuart J Gallagher, et al.
The British Journal of Dermatology|December 18, 2021
Independent evaluation of melanoma polygenic risk scores in UK and Australian prospective cohortsJulia Steinberg, Mark M Iles, Jin Yee Lee, et al.
Pageof 19